Walnut, CA—Farlong Pharmaceutical has announced the results of a study examining the effects of its branded notoginseng extract on cholesterol and blood pressure.
The randomized, placebo-controlled, triple-blind study was published in Current Nutraceuticals Journal. It was performed on 95 healthy adults.
The study demonstrated that Farlong NotoGinseng supplementation improved blood pressure, significantly lowered serum LDL cholesterol, and slightly raised serum HDL cholesterol. 17.5% of those in the treatment group saw improvement in all three CVD risk factors, compared to 5% of those on placebo, by week 12. It was well-tolerated.
The study will be presented at the American Heart Association’s annual Scientific Sessions 2021, taking place November 13-15, with a global audience from over 100 countries. The study’s abstract will also be published in Circulation.